A GnRH agonist, leuprolide acetate, has been tested in phase 2 clinical trials of late-onset AD; the results showed that high dose Lupron in combination with acetylcholinesterase inhibitors reduces cognitive decline in women28. This evidence concerns the gene ACHE and Mental deterioration.